Activation of the alternative pathway of human complement by autologous cells expressing transmembrane recombinant properdin

被引:12
作者
Vuagnat, BB [1 ]
Mach, JP [1 ]
Le Doussal, JM [1 ]
机构
[1] Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland
关键词
complement; alternative pathway; properdin; immunotherapy;
D O I
10.1016/S0161-5890(00)00069-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Properdin (P) is a serum glycoprotein thai stabilizes the labile C3 convertase (C3bBb) of the alternative pathway of the complement system (AP). Thanks to its oligomeric nature, P specifically upregulates AP on surfaces without activating AP in the fluid-phase. We investigated whether human cells, displaying P at their membrane, could activate autologous AP. The cDNAs encoding human P and the transmembrane domain of human platelet derived growth factor receptor were fused together and expressed in human embryo kidney cells (HEK-293). Selected cells displayed P at their surface as shown by FAGS. In contact with human serum at 37 degreesC, they triggered AP-mediated C3 deposition. SDS-PAGE analysis showed C3 covalently bound to various membrane proteins, but not to P itself. However, displayed P affinity could bind to serum or purified C3i at 4 degreesC. C3 binding was restricted to the cells displaying P, was inhibited by an anti-P mAb, and did not require serum P. Bound C3 allowed further C5, C7 and C9 deposition as well as cell lysis after blocking CD59 function. In contrast, wild-type cells, cells displaying factor D or truncated P (deleted from its 6th thrombospondin-like repeat) did not activate AP. We hypothesize that displayed P activates AP by stabilizing bystander C3b and/or by capturing serum C3iBb convertase. Finally, we suggest that P could be used for retargeting autologous complement to AP-resistant pathogens and tumor cells. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:467 / 478
页数:12
相关论文
共 49 条
[31]  
PANGBURN MK, 1989, J IMMUNOL, V142, P2759
[32]  
PANGBURN MK, 1989, J IMMUNOL, V142, P202
[33]   THE C3-CONVERTASE OF THE ALTERNATIVE PATHWAY OF HUMAN-COMPLEMENT - ENZYMATIC-PROPERTIES OF THE BIMOLECULAR PROTEINASE [J].
PANGBURN, MK ;
MULLEREBERHARD, HJ .
BIOCHEMICAL JOURNAL, 1986, 235 (03) :723-730
[34]   INHIBITION OF COMPLEMENT ALTERNATIVE PATHWAY IN MICE WITH FAB ANTIBODY TO RECOMBINANT ADIPSIN FACTOR-D [J].
PASCUAL, M ;
CATANA, E ;
WHITE, T ;
SPIEGELMAN, BM ;
SCHIFFERLI, JA .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1993, 23 (06) :1389-1392
[35]   A MONOCLONAL-ANTIBODY WHICH BLOCKS THE FUNCTION OF FACTOR-D OF HUMAN-COMPLEMENT [J].
PASCUAL, M ;
CATANA, E ;
SPERTINI, F ;
MACON, K ;
VOLANAKIS, JE ;
SCHIFFERLI, JA .
JOURNAL OF IMMUNOLOGICAL METHODS, 1990, 127 (02) :263-269
[36]  
REITER Y, 1989, J IMMUNOL, V142, P2771
[37]   THE MACROPHAGE-ATTACHMENT GLYCOPROTEIN GP63 IS THE PREDOMINANT C3-ACCEPTOR SITE ON LEISHMANIA-MEXICANA PROMASTIGOTES [J].
RUSSELL, DG .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1987, 164 (01) :213-221
[38]   SPECIFICITY OF THE THIOESTER-CONTAINING REACTIVE-SITE OF HUMAN C3 AND ITS SIGNIFICANCE TO COMPLEMENT ACTIVATION [J].
SAHU, A ;
KOZEL, TR ;
PANGBURN, MK .
BIOCHEMICAL JOURNAL, 1994, 302 :429-436
[39]  
Sahu A, 1998, J IMMUNOL, V160, P5596
[40]   COVALENT BINDING OF C3B TO MONOCLONAL-ANTIBODIES SELECTIVELY UP-REGULATES HEAVY-CHAIN EPITOPE RECOGNITION BY T-CELLS [J].
SANTORO, L ;
DROUET, C ;
REBOUL, A ;
MACH, JP ;
COLOMB, MG .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1994, 24 (07) :1620-1626